Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 220

1.

Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era.

Bedimo RJ, Westfall AO, Drechsler H, Vidiella G, Tebas P.

Clin Infect Dis. 2011 Jul 1;53(1):84-91. doi: 10.1093/cid/cir269.

PMID:
21653308
2.

Renal toxicity of long-term therapy with tenofovir in HIV-infected patients.

Monteagudo-Chu MO, Chang MH, Fung HB, Bräu N.

J Pharm Pract. 2012 Oct;25(5):552-9. Epub 2012 May 2.

PMID:
22551561
3.

Renal function declines more in tenofovir- than abacavir-based antiretroviral therapy in low-body weight treatment-naïve patients with HIV infection.

Nishijima T, Gatanaga H, Komatsu H, Tsukada K, Shimbo T, Aoki T, Watanabe K, Kinai E, Honda H, Tanuma J, Yazaki H, Honda M, Teruya K, Kikuchi Y, Oka S.

PLoS One. 2012;7(1):e29977. doi: 10.1371/journal.pone.0029977. Epub 2012 Jan 5.

4.

Early changes in inflammatory and pro-thrombotic biomarkers in patients initiating antiretroviral therapy with abacavir or tenofovir.

Padilla S, Masiá M, García N, Jarrin I, Tormo C, Gutiérrez F.

BMC Infect Dis. 2011 Feb 4;11:40. doi: 10.1186/1471-2334-11-40.

5.

Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: a population-based nationwide cohort study.

Obel N, Farkas DK, Kronborg G, Larsen CS, Pedersen G, Riis A, Pedersen C, Gerstoft J, Sørensen HT.

HIV Med. 2010 Feb;11(2):130-6. doi: 10.1111/j.1468-1293.2009.00751.x. Epub 2009 Aug 13.

6.

Renal function and incidence of chronic kidney disease in HIV patients: a Danish cohort study.

Rasch MG, Engsig FN, Feldt-Rasmussen B, Kirk O, Kronborg G, Pedersen C, Gerstoft J, Obel N.

Scand J Infect Dis. 2012 Sep;44(9):689-96. doi: 10.3109/00365548.2012.673730. Epub 2012 Jun 10.

PMID:
22680981
7.

Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons.

Choi AI, Vittinghoff E, Deeks SG, Weekley CC, Li Y, Shlipak MG.

AIDS. 2011 Jun 19;25(10):1289-98. doi: 10.1097/QAD.0b013e328347fa16.

8.

A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression.

Martínez E, Arranz JA, Podzamczer D, Loncá M, Sanz J, Barragán P, Ribera E, Knobel H, Roca V, Gutiérrez F, Blanco JL, Mallolas J, Llibre JM, Clotet B, Dalmau D, Segura F, Arribas JR, Cosín J, Barrufet P, Casas E, Ferrer E, Curran A, González A, Pich J, Cruceta A, Arnaiz JA, Miró JM, Gatell JM; BICOMBO Study Team.

J Acquir Immune Defic Syndr. 2009 Jul 1;51(3):290-7. doi: 10.1097/QAI.0b013e3181aa12d5.

PMID:
19398921
9.

Association between HIV infection, antiretroviral therapy, and risk of acute myocardial infarction: a cohort and nested case-control study using Québec's public health insurance database.

Durand M, Sheehy O, Baril JG, Lelorier J, Tremblay CL.

J Acquir Immune Defic Syndr. 2011 Jul 1;57(3):245-53. doi: 10.1097/QAI.0b013e31821d33a5.

PMID:
21499115
10.

Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy.

Pavie J, Porcher R, Torti C, Medrano J, Castagna A, Valin N, Rusconi S, Ammassari A, Ghosn J, Delaugerre C, Molina JM; NEAT Unboosted Atazanavir Cohort Study Group.

J Antimicrob Chemother. 2011 Oct;66(10):2372-8. doi: 10.1093/jac/dkr316. Epub 2011 Aug 5.

11.

[Current data on antiretroviral therapy. CROI 2009: tenofovir DR convinces by high effectiveness and tolerance].

Walter M.

MMW Fortschr Med. 2009 Apr 30;151(18):76-9. German. No abstract available.

PMID:
19769084
12.

Impact of small body weight on tenofovir-associated renal dysfunction in HIV-infected patients: a retrospective cohort study of Japanese patients.

Nishijima T, Komatsu H, Gatanaga H, Aoki T, Watanabe K, Kinai E, Honda H, Tanuma J, Yazaki H, Tsukada K, Honda M, Teruya K, Kikuchi Y, Oka S.

PLoS One. 2011;6(7):e22661. doi: 10.1371/journal.pone.0022661. Epub 2011 Jul 25.

13.

A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy.

Moyle GJ, Sabin CA, Cartledge J, Johnson M, Wilkins E, Churchill D, Hay P, Fakoya A, Murphy M, Scullard G, Leen C, Reilly G; RAVE (Randomized Abacavir versus Viread Evaluation) Group UK.

AIDS. 2006 Oct 24;20(16):2043-50.

PMID:
17053350
14.

Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4.

Lang S, Mary-Krause M, Cotte L, Gilquin J, Partisani M, Simon A, Boccara F, Costagliola D; Clinical Epidemiology Group of the French Hospital Database on HIV.

Arch Intern Med. 2010 Jul 26;170(14):1228-38. doi: 10.1001/archinternmed.2010.197.

PMID:
20660842
15.

Effect of abacavir on acute changes in biomarkers associated with cardiovascular dysfunction.

Patel P, Bush T, Overton T, Baker J, Hammer J, Kojic E, Conley L, Henry K, Brooks JT; SUN Study Investigators.

Antivir Ther. 2012;17(4):755-61. doi: 10.3851/IMP2020. Epub 2011 Dec 16.

PMID:
22301072
16.

Comparison of abacavir/lamivudine and tenofovir/emtricitabine among treatment-naive HIV-infected patients initiating therapy.

Tan DH, Chan K, Raboud J, Cooper C, Montaner JS, Walmsley S, Hogg RS, Klein MB, Machouf N, Rourke SB, Tsoukas C, Loutfy MR; CANOC Collaboration.

J Acquir Immune Defic Syndr. 2011 Sep 1;58(1):38-46. doi: 10.1097/QAI.0b013e3182282cfc.

PMID:
21709570
17.

Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial.

Martin A, Bloch M, Amin J, Baker D, Cooper DA, Emery S, Carr A.

Clin Infect Dis. 2009 Nov 15;49(10):1591-601. doi: 10.1086/644769.

PMID:
19842973
18.

Improvement in bone mineral density after switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: two-centre randomized pilot study (OsteoTDF study).

Negredo E, Domingo P, Pérez-Álvarez N, Gutiérrez M, Mateo G, Puig J, Escrig R, Echeverría P, Bonjoch A, Clotet B.

J Antimicrob Chemother. 2014 Dec;69(12):3368-71. doi: 10.1093/jac/dku300. Epub 2014 Aug 13.

PMID:
25125679
19.

No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT.

Ribaudo HJ, Benson CA, Zheng Y, Koletar SL, Collier AC, Lok JJ, Smurzynski M, Bosch RJ, Bastow B, Schouten JT; ACTG A5001/ALLRT Protocol Team.

Clin Infect Dis. 2011 Apr 1;52(7):929-40. doi: 10.1093/cid/ciq244.

20.

Supplemental Content

Support Center